NEW YORK, Dec. 30 (GenomeWeb News) - Genome Therapeutics and Genesoft Pharmaceuticals today announced that the US Securities and Exchange Commission has approved a registration statement related to their proposed merger that includes a proxy statement that will be mailed to shareholders of both companies.

In addition, the companies said they will each hold a special meeting of their stockholders to vote on the proposed merger and other related matters on Feb. 2, 2004.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.